PRECIGEN, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
PRECIGEN, INC. (PGEN) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $2.05 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-04
- PRECIGEN, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $2.21, a 97.32% increase year-over-year.
- PRECIGEN, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $1.12.
- PRECIGEN, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $0.00.
- PRECIGEN, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $1.53, a 17.69% increase from fiscal 2024.
- PRECIGEN, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $1.30.
- PRECIGEN, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $0.00.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.05 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | $2.21 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $1.53 10-K · filed 2026-03-25 | |||
| 2025-09-30 | $1.54 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $1.15 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | $1.12 10-Q · filed 2025-05-14 | |||
| 2024-12-31 | $1.30 10-K · filed 2026-03-25 | |||
| 2024-09-30 | $1.30 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | $1.42 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-03-25 | |||
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |